BIO KEY INTERNATIONAL INC (BKYI): Nasdaq/NYSE listing notice — BIO-key receives additional 180-day Nasdaq compliance period until Jan 8, 2024 for bid price rule

BIO KEY INTERNATIONAL INC

Received deficiency letter on Jan 12, 2023 for bid price below $1.00 for 30 consecutive days.
On July 12, 2023, Nasdaq granted additional 180-day period until Jan 8, 2024 to regain compliance.
To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
Company may effect reverse stock split to cure deficiency if needed.
If not compliant by Jan 8, 2024, Nasdaq will delist and company can appeal.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIO KEY INTERNATIONAL INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 12, 2023, the Company received a letter from Nasdaq (the “Letter”) stating that although the Company had not regained compliance with the Bid Price Rule, Nasdaq determined that the Company is eligible for an additional 180-day period, or until January 8, 2024, to regain compliance with the Bid Price Rule. In the Letter, Nasdaq stated that its determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimum

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO KEY INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-019971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.